<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3896">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04403061</url>
  </required_header>
  <id_info>
    <org_study_id>EC128/20</org_study_id>
    <nct_id>NCT04403061</nct_id>
  </id_info>
  <brief_title>Th1/Th2/Th17/TREG and TLRs Activation/KIR for COVID 19 Prediction of Outcome</brief_title>
  <acronym>Resistir</acronym>
  <official_title>Th1/Th2/Th17/TREG Response and TLRs Activation/KIR Receptors for Predicting the Evolution of the SARS Cov-2 Infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asociacion para el Estudio de las Enfermedades Infecciosas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Asociacion para el Estudio de las Enfermedades Infecciosas</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To ascertain globally the changes in the cytokines involved and TLRs/KIR activation in&#xD;
      patients admitted to the hospital with a COVID-19 diagnosis, and the changes after initiation&#xD;
      of the different therapies&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      COVID-19 is a disease with an initial viral phase followed, usually at the 7th day, of an&#xD;
      inflammatory state (cytokine storm) leading to respiratory distress, ICU admission and risk&#xD;
      of death. Thus, several biological agents, antagonists of the different cytokines (IL-6,&#xD;
      IL-1) have been used for patients with severe disease. However, there are no data about the&#xD;
      cytokine changes, at admission and after therapy, and its predictive value, a fundamental&#xD;
      knowledge to establish the best therapeutic strategy.&#xD;
&#xD;
      The first line of immune defense is the interaction of the virus with innate immunity cell&#xD;
      members. The toll like receptors (TLRs) family is a group of pattern recognition receptors&#xD;
      that include many different molecules (21-23). These bindings can activate dendritic cells,&#xD;
      monocytes, macrophages. There is an important RNA and DNA connection, activation of TLRs, the&#xD;
      production of type I interferons, and the development of some autoimmune diseases. TLR7 and&#xD;
      TLR8 specifically recognize simple-chain RNA of viruses and are expressed in endosomal&#xD;
      membranes. TLR8 is expressed in regulatory cells (Treg) and its activation results in&#xD;
      inhibition of its regulatory functions. Natural killer cells (NK) respond to alterations of&#xD;
      class I HLA molecules present in infected cells (24-26). An increase in class I HLA&#xD;
      expression could lead to an increase in NK activation by increasing its ability to produce&#xD;
      IFN-gamma. Therefore, the reasons for KIR binding are often variable between individuals and&#xD;
      between populations.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 22, 2020</start_date>
  <completion_date type="Actual">January 10, 2021</completion_date>
  <primary_completion_date type="Actual">December 22, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in cytokines associated with SARS CoV-2 infection</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of cellular response</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>TLRs activation</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>KIR phenotype determination</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <enrollment type="Actual">106</enrollment>
  <condition>Disease, Viral</condition>
  <condition>Cytokine Release Syndrome</condition>
  <condition>TLRs</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Cytokines measurement</intervention_name>
    <description>Quantification of plasma cytokine levels of human GM-CSF, IFN-α, IFN-γ, IL-2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12p70, IL-17A, and TNF-α using multiplex technol-ogy (quantitative measure).</description>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Cellular response</intervention_name>
    <description>SARS-CoV-2 peptides (Prot-S, Pros-N and Port-M) will be used to activate CD4 and CD8 T cells. Cytokines released, such as IFNg, TNFa, IL4, IL17A, and IL2, from each cell subset will be measured by flow cytometry (quantitative measure).</description>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>TLRs activation measurement</intervention_name>
    <description>After specific cell activation through TLR7/8 receptors, such as resiquimod, ORN R-0002, ORN R-0006, ORN R-1263, ORN R-2336, and controls as Poly (I:C), the release of IFNa, IFNg, TNFa, IL12, and IL6 will be analyzed (quantitative measure).</description>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>KIR phenotype evaluation</intervention_name>
    <description>Characterization of the presence of 14 genes plus 2 pseudogenes of KIR gene family (qualitative genotyping) by PCR, mRNA expression profiling (quantitative measures) by RT-PCR, and phenotyping of human NK cells analyzing different KIR receptors (quantitative measure) by flow cytometry, will be analyzed.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with a diagnosis of COVID-19&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with a diagnosis of COVID-19 (PCR confirmed)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No informed consent&#xD;
&#xD;
          -  Presence of chronic therapy with immunomodulators, corticoids or antineoplastic&#xD;
             agents.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>May 23, 2020</study_first_submitted>
  <study_first_submitted_qc>May 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 27, 2020</study_first_posted>
  <last_update_submitted>January 11, 2021</last_update_submitted>
  <last_update_submitted_qc>January 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Pending to establish collaboration to share cytokine measurements</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

